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Combined pituitary hormone deficiency due to gross
deletions in the POU1F1 (PIT-1) and PROP1 genes
Eleonore Bertko1, Jürgen Klammt1, Petra Dusatkova2, Mithat Bahceci3, Nazli Gonc4, Louise ten Have5,
Nurgun Kandemir4, Georg Mansmann6, Barbora Obermannova2, Wilma Oostdijk7, Heike Pfäffle1,
Denise Rockstroh-Lippold1, Marina Schlicke1, Alpaslan Kemal Tuzcu8 and Roland Pfäffle1
Pituitary development depends on a complex cascade of interacting transcription factors and signaling molecules. Lesions in this
cascade lead to isolated or combined pituitary hormone deficiency (CPHD). The aim of this study was to identify copy number
variants (CNVs) in genes known to cause CPHD and to determine their structure. We analyzed 70 CPHD patients from 64
families. Deletions were found in three Turkish families and one family from northern Iraq. In one family we identified a 4.96 kb
deletion that comprises the first two exons of POU1F1. In three families a homozygous 15.9 kb deletion including complete
PROP1 was discovered. Breakpoints map within highly homologous AluY sequences. Haplotype analysis revealed a shared
haplotype of 350 kb among PROP1 deletion carriers. For the first time we were able to assign the boundaries of a previously
reported PROP1 deletion. This gross deletion shows strong evidence to originate from a common ancestor in patients with
Kurdish descent. No CNVs within LHX3, LHX4, HESX1, GH1 and GHRHR were found. Our data prove multiplex ligation-
dependent probe amplification to be a valuable tool for the detection of CNVs as cause of pituitary insufficiencies and should be
considered as an analytical method particularly in Kurdish patients.
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INTRODUCTION
The human pituitary gland is a central regulator of growth, fertility,
stress response and metabolism. Development of the pituitary gland
depends on a precise algorithm of interacting transcription factors and
signaling molecules. Mutations in any of the genes involved in
pituitary development lead to pituitary insufficiency resulting in
reduced or entirely missing secretion of pituitary hormones.
Deficiency of GH in combination with a deficiency in one or more
additional anterior pituitary-derived hormones is called combined
pituitary hormone deficiency (CPHD). Epidemiology of CPHD is
not entirely clear, in part due to marked regional differences in
prevalence;1 however, genetic causes are not uncommon. It evolves
from a diversity of transcription factor mutations in genes such as
PROP1, POU1F1 (PIT-1), HESX1, LHX3 and LHX4.2–4 Whereas
PROP1 and LHX3 mutations cause autosomal recessively inherited
CPHD, for HESX1, POU1F1, and most recently also for LHX4
mutations both dominant and recessively inherited hypopituitarism
has been reported.5–7
The most frequent genetic cause of CPHD is defects of PROP1,
which is located on the long arm of chromosome 5 (5q35.3) and
consists of three exons spanning a region of ~ 4 kb. Translation
product of PROP1 gene is a paired-like homeodomain protein, which
is involved in the development of pituitary gonadotropes, somato-
tropes, lactotropes and thyrotropes. Prop1-deficient Ames dwarf mice
(df/df) are characterized by severe dwarfism and infertility.8
In humans, defects in PROP1 result in a deficiency of GH, TSH,
FSH/LH and prolactin (PRL). ACTH deficiency can evolve in some
patients.9 Onset and severity of hormone deficiencies as well as
changes in pituitary morphology are variable with temporary enlarge-
ment of the anterior lobe reported especially in pediatric patients.10–14
To date, various PROP1 point mutations, small deletions and
insertions have been reported with a remarkably uneven regional/
ethnic distribution of specific variants.2,13,15 Complete homozygous
deletion of PROP1 was described six times, but exact deletion
breakpoints have yet to be identified.16–21
POU1F1 (also known as PIT-1), which belongs to the POU
homeodomain protein family, regulates transcription via complex
protein–DNA and protein–protein interactions mediated by its
POU-specific and POU-homeo domains. POU1F1 is located on the
short arm of chromosome 3 (3p11), contains six exons and spans
a region of ~ 17 kb. POU1F1 is required for formation of pituitary
somatotropes, thyrotropes and lactotropes. Snell (dw/dw) and Jackson
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(dwj/dwj) dwarf mice, harboring Pou1f1 mutations, present with
greatly reduced size and hypothyroidism.22 Comparable clinical
characteristics are found in humans carrying POU1F1 mutations.
They often present with severe growth impairment.23–25 GH and
PRL deficiencies are generally complete, but the onset of clinical
hypothyroidism is highly variable.25 Human POU1F1 mutation
carriers display hypoplastic or normal adenohypophysis with normal
pituitary stalk and posterior pituitary.24–26 Several studies have
investigated the frequency of POU1F1 mutations in CPHD patients,5
but there are only three reports about POU1F1 gross deletions.17,23,27
Aim of the study was to determine the occurrence of homozygous
or heterozygous copy number variants (CNVs) in genes known to
cause hypopituitarism in a cohort of patients with CPHD.
MATERIALS AND METHODS
A total of 70 patients from 64 families (38 males and 32 females) diagnosed
with CPHD were analyzed for the occurrence of CNVs in genes established to
cause hypopituitarism (PROP1, POU1F1, LHX3, LHX4, GH1 and GHRHR).
We selected patients at the more severe end of the phenotypic spectrum, who
are affected by GH deficiency and at least two additional hormone deficiencies
including TSH (94%), gonadotropins (69%), ACTH (63%) and PRL (46%).
DNA of seven patients was included in the study, for which PCR amplification
of an entire gene or specific exons had failed in the past. Further 63 patients
with CPHD were included in the study, in whom previously neither point
mutations nor small deletions or insertions were found by dHPLC screening
and direct sequencing in the genes for PROP1, POU1F1, HESX1 and LHX3.
Studies were conducted with informed consent of the probands or their
parents.
Mutation analysis
Genomic DNA was isolated from peripheral blood cells. Multiplex ligation-
dependent probe amplification (MLPA) assays were performed using MLPA kit
P216-A2 containing probes for exons of GH1 (except exon 2), PROP1, POU1F1
(except exon 5), GHRHR (except exon 8), HESX1, LHX3 (except exon 1) and
LHX4 following the protocol provided by MRC Holland (Amsterdam, the
Netherlands). GH1 and GHRHR were included in the analyses because they are
part of MRC Holland’s growth hormone deficiency multiplex panel and,
moreover, specific autosomal-dominant GH1 mutations have been described to
cause an evolving CPHD-like phenotype with multiple pituitary hormone
deficiencies.28 MLPA products were run on ABI Prism 310 sequencer
and analyzed using PeakScanner version 1.0 and Coffalyser software
(Applied Biosystems, Foster City, CA, USA). Direct sequencing of deletion
breakpoints was performed according to a slightly modified manufacturer’s
protocol (ABI 310, Applied Biosystems). Sequence data were compared to the
genomic reference assembly (March 2006 NCBI36/hg18; accessed through the
UCSC Genome Browser (URL: http://genome.ucsc.edu/)) employing Vector
NTI Advance software (Life Technologies, Darmstadt, Germany).
Mapping of POU1F1 deletion
Primer pairs for PCR markers D1 through D6 upstream of exon 1 and
downstream of exon 2 of POU1F1 (NM_000306) were designed based on the
human genomic assembly (March 2006 NCBI36/hg18). Long-range PCR was
performed using Roche’s Expand Long Template PCR System according to the
manufacturer’s instructions (Roche Diagnostics, Mannheim, Germany). Primer
sequences are provided in the (Supplementary Table S1).
Mapping of PROP1 gross deletion
To narrow down deletion breakpoints we used STS markers and primer pairs
described previously16 with some minor modifications (primer sequences
provided in the Supplementary Table S1). In the PROP1 upstream region this
strategy was limited by a 51 kb duplicated region containing the FAM153C
(family with sequence similarity 153) pseudogene that impedes selection of
specific PCR primers (for location of PCR markers compare Figure 4a).
Therefore, inverse PCR starting from the R4 downstream region was
performed. Briefly, genomic DNA was digested with the restriction enzyme
NspI and restriction fragments were circulated under conditions favoring self-
ligation. The resulting circular monomers were used as template for PCR
amplification using primers complementary to the R4 sequence
but pointing outwards (inverse, R4inv). The resulting PCR fragment was
re-amplified with nested primers followed by direct sequencing, thereby
disclosing the nearest distally located NspI site that is not affected by the
deletion. Knowing the region between the last absent and the first present
upstream NspI recognition sequence facilitated the assignment of the upstream
breakpoint to a range of 3.8 kb. Three additional reverse primers
(P15R, 15.4 kb distal of R4 in the wild-type sequence; P17R, 17.4 kb distal of
R4; P18R, 18.2 kb distal of R4) were designed and applied in long-range PCRs
using R4F as forward primer. Data obtained by direct sequencing of the
shortest resulting PCR product cloned into pGEM-T vector (Promega,
Mannheim, Germany) were aligned with the genomic reference sequence
(build NCBI36/hg18) to define the deletion boundaries. Details of inverse and
nested PCR primer pairs as well as sequences of long-range PCR primers are
provided as (Supplementary Table S1).
Figure 1 Phenotype and pedigree of case 1. (a) Index patient (case 1) at the age of 11 years and 7 months, 3 months after starting rhGH therapy and at the
age of 12 years and 3 months, 1 year after starting therapy (left and right photograph, respectively; with consent of the family). (b) Pedigree of the family of
case 1. Arrow indicates the index patient. Half-black symbols mark unaffected heterozygous carriers of the POU1F1 deletion. DNA of the healthy mother was
not available for analysis. A full color version of this figure is available at the Journal of Human Genetics journal online.
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Haplotype analysis
Haplotypes were constructed using 7 microsatellite (STR; Supplementary
Table S2) and 22 SNP markers flanking the PROP1 deletion and spanning
a region of ~ 9.6 Mb (identified using UCSC genome browser (http://genome.
ucsc.edu/, GRCh37/hg19)). Fragment length analysis of STR markers was
performed on an automated sequencer (ABI 310, Applied Biosystems) using
FAM-labeled primers, data were analyzed using GeneScan version 3.1 and
GeneMapper software version 4.1 (Applied Biosystems). SNPs were genotyped
by allele-specific quantitative PCR (Applied Biosystems, Carlsbad, CA, USA)
and analyzed by Phase software as described previously.29
RESULTS
MLPA analysis revealed six patients, belonging to three families,
carrying a homozygous deletion of the complete PROP1 gene. One
further patient was identified with a homozygous deletion of exon
1 and 2 of the POU1F1 gene. CNV analysis of the remaining genes did
not yield any aberration in our patients, neither in a homozygous nor
in a hemizygous or compound hemizygous state. Detailed clinical case
presentations of deletion carriers are available in the Supplementary
Information.
Clinical evaluation
Case 1. A boy from a consanguineous Turkish pedigree, the only
affected child of seven siblings, presented at first evaluation at
11.5 years of age with an extreme growth retardation of − 11.43 SDS
(Figure 1a). Laboratory analysis of pituitary hormones suggested
complete or nearly complete loss of somatotrope, lactotrope and
thyrotrope, but normal corticotrope and gonadotrope function
(Table 1). Magnetic resonance imaging (MRI) revealed a hypoplastic
anterior pituitary gland. Parents of the patient are first cousins and
clinically healthy (Figure 1b). Three brothers died during infancy with
no information available about their cause of death. MLPA analysis of
the index patient yielded no signal for exons 1 and 2 of POU1F1. The
father and two brothers, all unaffected, were found to be hemizygous
in these exons. DNA of the mother was not available.
Case 2. Clinical evaluation of a 40-year-old patient from northern
Iraq showed an apparently hypogonadal man with short stature
(139.4 cm, − 5.5 SDS). Laboratory results confirmed hypogonadotro-
pic hypogonadism with low stimulated LH and FSH, and testosterone
below the detection limit. Further dynamic testing of pituitary
function demonstrated somatotrope, thyrotrope and lactotrope
insufficiency. The pituitary–adrenocortical axis was not affected
(Table 1). X-ray of the left hand revealed a skeletal age of 14.4 years
(Figure 2a) in line with juvenile levels of bone-specific alkaline
phosphatase (79.6 μg l− 1). MRI showed severe hypoplasia of the
anterior pituitary lobe; the posterior pituitary and the pituitary stalk
appeared normal (Figure 2b). Failure to amplify genomic DNA of the
index patient in the PROP1 locus was paralleled by MLPA analysis
disclosing biallelic loss of all three PROP1 exons.
Case 3. A boy from the southeast part of Turkey born to
consanguineous, normal statured parents showed retarded growth
(height 81 cm, − 4.17 SDS) at first presentation at 3.4 years of age.
Laboratory analyses demonstrated deficiency of GH (Table 1).
TSH and fT4 testing revealed secondary hypothyroidism, whereas
PRL serum levels were in the lower physiological range. Initial
ACTH stimulation test was normal but became pathological when
repeated at 13 years of age (peak cortisol of 373.3 nmol l− 1,
normal4500 nmol l− 1). MRI revealed hypoplasia of the anterior
pituitary lobe but normal pituitary stalk and neurohypophysis
(Figure 2c). No additional family members are affected by CPHD.
However a sister of the patient died at 5 months of age and a brother
died shortly after birth. MLPA analysis confirmed previous PCR
results that had suggested complete, homozygous loss of PROP1.
Case 4. Four affected children (one girl, three boys) were born to
a consanguineous Turkish marriage (parents are first cousins;
Table 1 Hormonal phenotypes of the patients including siblings of case 4
Case 1 Case 2 Case 3
Family 4
(IV/1) (IV/5) (IV/6) (IV/12)a
Age (yrs) 11.5 40 3.5 14 34 31 17
Sex (m/f) m m m f m m m
Gene mutated POU1F1 PROP1 PROP1 PROP1 PROP1 PROP1 PROP1
GH, basal (μg l−1) NA o0.05 NA o0.05 o0.05 0.40 0.40
GH, stim. (μg l−1) o0.20 0.21 o1.00 NA NA NA NA
TSH (mIU l−1) o0.50b 0.38
0.94b
1.15 (0.3–2.5) 0.01 (0.3–2.5) o0.005 (0.3–2.5) 0.39 (0.3–2.5) 0.01 (0.3–2.5)
T4
Total T4 (nmol l−1) o10 (60–150) NA NA NA NA NA NA
Free T4 (pmol l−1) NA 2.19 (12–25) 5.57 (10–23) NA NA NA NA
LH (IU l−1) 0.30 (0.5–5.3) o0.10b (43.0) o0.07 (o0.5) 0.89 (0.5–9.0) 0.70 (1.5–9.3) 0.10 (1.5–9.3) 0.10 (0.5–5.3)
FSH (IU l−1) 1.30 (0.4–6.6) 0.20b (44.9) o0.07 (o2.2) 0.10 (1.4–9.2) 0.20 (0.3–8.5) 4.45 (0.3–8.5) 0.10 (1.4–9.2)
ACTH (pmol l−1) 6.82 (1.6–14.2) 3.06 (1.6–13.9) NA 2.21 (1.6–14.2) 8.43 (1.6–14.2) 6.21 (1.6–14.2) 4.71 (1.6–14.2)
Cortisol (nmol l−1) 500.0b (4500) 537.6b (4500) 766b (4500) NA NA NA NA














MRI, anterior pituitary Hypoplastic Hypoplastic Hypoplastic Near normal NA Enlarged Near normal
Abbreviations: ACTH, adrenocorticotrope hormone; FSH, follicle-stimulating hormone; GH, growth hormone, LH, luteinizing hormone; MRI, magnetic resonance imaging; NA, not available; PRL,
prolactin; TSH, thyroid-stimulating hormone.
aIndex patient.
bStimulated. Laboratory measurements were performed using different assays. Reference values (in parenthesis) are just given for overall guidance.
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Figure 5). At 11 years of age the male index patient presented with a
growth retardation of − 4.68 SDS (114 cm). At 17 years he did not
show any signs of puberty onset. Laboratory tests revealed deficiency
of GH, TSH, gonadotropins and PRL, whereas ACTH secretion
was normal (Table 1). His affected siblings also had—to a variable
extent—somatotrope, thyrotrope and gonadotrope insufficiency but
none of them, including those who had already reached adulthood,
have developed adrenal insufficiency. Available MR images disclosed
nearly normal-sized anterior pituitaries in the index patient and his
sister (Figure 2d) but a slightly enlarged adenohypophysis in brother
IV/6 (Figure 2e). MLPA analyses performed in parents and all but one
sibling revealed complete loss of PROP1 in the affected individuals and
hemizygous PROP1 deletion in four unaffected brothers, in a healthy
sister and the parents. A further sister and brother were biallelic
carriers of the wild-type gene.
POU1F1 deletion analysis
To define the extent of the deletion identified in the index patient
(case 1) and to ascertain adjacent regions affected by the deletion
various PCR markers down- and upstream of the two failing
MLPA probes were analyzed (Figure 3a). All PCR markers were
detectable in the sample of the index patient. Long-range PCR using
forward and reverse primers of markers D3 and D4, respectively,
yielded the expected fragment of ~ 6.1 kb in a WT sample and a 1.2 kb
product in the patient’s DNA predicting a deletion of ~ 4.9 kb. Direct
sequencing revealed the deleted sequence to encompass 4958 bp
including exon 1 and 2, and ~ 1.3 kb of the POU1F1 upstream region
(c.-1387_214+455del; Figure 3b). The deletion breakpoint within
intron 2 resides within a MER3 (MEdium Reiteration frequency
interspersed repeat) subfamily region of repetitive elements
(RepeatMasker through UCSC Genome Browser: http://genome.
ucsc.edu/; accessed December 2014), whereas the upstream breakpoint
is apparently not part of a repeating element. Although neither
breakpoint is part of a typical recombination hot spot, it appears
possible that the AG dinucleotide found at both sites and/or the MER3
interspersed repeat located within the intron 2 breakpoint may have
contributed to the DNA excision event. No additional genes were
affected by the deletion.
PROP1 deletion analysis
To study the extent of the deletion found in the index patient of family
4, various PCR and STS markers around the PROP1 locus were tested
(Figure 4a). The PCR probes closest to PROP1 that were unambigu-
ously amenable to PCR amplification were R4 located ~ 2.2 kb
downstream the PROP1 locus and WI-16216 that maps ~ 60 kb
upstream. Due to the presence of the pseudogene FAM153C,
which is highly homologous to two distinct chromosomal loci
(FAM153A: 5q35.3, FAM153B: 5q35.2), additional upstream
located PCR probes were not informative. By employing inverse
PCR and subsequent long-range PCRs that attained specificity
through the forward primer located within the R4 region, we
were eventually able to define the range of the deletion (Figure 4b).
Direct sequencing disclosed a deleted fragment of 15 892 bp
[chr5:177419141_177435032del (GRCh37/hg19)] (Figure 4c). The
breakpoints of the deletion map to an AluY repetitive element that
resides ~ 11.5 kb upstream of the PROP1 transcription start site within
the first intron of the FAM153C pseudogene and an AluY element
immediately juxtaposed to the 3ʹ-end of PROP1 (569–587 bp
downstream of the stop codon). The two AluY elements have the
same direction on the chromosome and an overall identity of 88%.
The fusion site of the deletion could be refined to an 18 bp sequence
that is completely homologous between both AluY (Figure 4c).
No other coding or non-coding genes were affected by the
deletion. Breakpoint spanning PCR revealed that all index
Figure 2 Imaging-based diagnostics of cases 2–4. (a) X-ray of the left hand of case 2 performed at the age of 40 years, demonstrating pronounced delay of
skeletal maturation; arrow, epiphyseal cartilage with incomplete endochondral ossification. (b–e) Magnetic resonance imaging of the sella turcica of case 2
(b) and case 3 (c) demonstrate severe hypoplasia, whereas sagittal scans of individual IV/1 (d) and IV/6 of family 4 (e) show a nearly normal-sized and
a slightly enlarged anterior lobe of the pituitary (arrows), respectively, but normal pituitary stalk and posterior lobe.
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patients of case 2 through 4 are carriers of the same deletion, whereas
DNA of a previously reported patient from India18 did not yield
a PCR product indicating either a larger deletion and loss of the
primer binding site(s) or a substantially smaller deletion that would
result in a large PCR product not amplifiable under the conditions
applied (Figure 4d).
Haplotype analysis
As all carriers of the PROP1 deletion bear the same (or a highly
similar) deletion and are reported to share a common geographic
and/or ethnic origin, we investigated whether the mutation can be
ascribed to a common ancestor (founder effect). Haplotypes were
determined by analysis of three proximal and four distal STR markers,
their phase was derived from the relatives of case 4 (Figure 5). Only
the nearest STR marker (D5S2008) that maps ~ 142 kb distal from
PROP1 was shared by all affected patients from the three independent
families (Figure 5). Subsequent STR markers in either direction
(D5S2034, 2.49 Mb proximally, and D5S2030, 0.38 Mb distally of
PROP1 located) differed in at least one patient. Typing of SNPs
revealed a shared haplotype spanning ~ 0.55 Mb from rs4507507 to
rs4976788 (the latter one mapping 0.15Mb distally from the
non-uniform D5S2030; not shown in Figure 5) thus confirming
STR mapping results in distal direction and further delimiting the
shared region in proximal direction. Taking both approaches together
the maximal shared region encompasses ~ 0.42 Mb from markers
rs11249784 to D5S2030. Of note, both allelic haplotypes of case 2,
whose familial relationship was not reported, differed substantially
arguing against close kinship among the paternal and maternal lineage
(Figure 5; data not shown).
Figure 3 Mapping of POU1F1 deletion. (a) Schematic of the POU1F1
genomic locus and sequence markers applied to define the deletion
boundaries (not drawn to scale). Arrow indicates the orientation of the gene
and position of exons (gray bars, exon 1 and 2 designated by X1 and X2).
Below the arrow location of the multiplex ligation-dependent probe
amplification (MLPA) markers M1 and M2 (red boxes) as well PCR markers
(D1–D6, blue boxes) is shown. All markers up- and downstream of the two
MLPA probes yielded a positive signal. PCR using forward and reverse
primers of markers D3 and D4, respectively, yielded a product ~5 kb shorter
than expected. Direct sequencing defined the deletion breakpoints
(arrowheads). (b) Electropherogram depicts the fusion site of the deletion
(open box) that contains an AG dinucleotide, which cannot be
unambiguously assigned to the 5ʹ- or 3ʹ-deletion breakpoint due to its
occurrence at both sites. Of the 14 nucleotides downstream of the AG
dinucleotide fusion site an additional single adenosine was found to be
deleted (open arrow head).
Figure 4 Mapping of PROP1 deletion. (a) Schematic of the PROP1 genomic organization (not drawn to scale). PCR/STS markers (open boxes) that were
amenable to PCR amplification are boxed in bold. Upstream of PROP1 the only previously established STS marker that yielded a PCR product and that
without any doubt could be assigned to the extended PROP1 locus was WI-16216. Inverse PCR of NspI restriction endonuclease digested and self-circulated
DNA fragments revealed preservation of a NspI site 18.2 kb distal of the inverse primer pair R4inv (right-hand gray arrow head). Thus, the upstream
breakpoint was narrowed down to a range of 3.8 kb (defined by the lack of the neighboring NspI site, open gray arrow head). (b) Long-range PCR with R4F
and three additional PCR reverse probes (green boxes) yielded a product for P17R and P18R, but not for P15R. (c) Direct sequencing of the shortest
product (R4F/P17R) disclosed the range of recombination (shown as frame in the electropherogram) within two AluY elements (gray boxes in panel a).
(d) PCR products of the same molecular weight were obtained from genomic DNA of case 2, 3 and 4 using R4F and P17R primers suggesting equal deletion
boundaries for these patients. PCR of the DNA of a previously published patient from India (PI) as well wild-type DNA (WT) did not result in the 1576 bp
fragment.
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DISCUSSION
MLPA analyses of 70 CPHD patients from 64 families revealed
causative CNVs in seven patients belonging to four families. Index
patients of three families were found to have a complete PROP1
deletion. One patient carries a POU1F1 gross deletion comprising
exons 1 and 2 of the gene and none of the patients harbored a CNV in
GH1, GHRHR, HESX1, LHX3 or LHX4.
Mutations in PROP1 are the most common genetic cause of CPHD
accounting for 11.2% of all so far analyzed CPHD patients
(meta-analysis performed in De Rienzo et al.30). However, depending
on the applied screening methodology and the investigated population
the prevalence of PROP1 mutations differs markedly ranging
from 0 (refs 31–33) to 64.8% in a Lithuanian population.34 These
differences are in some populations closely linked to the occurrence of
a specific genetic aberration; for example, all of the 47 affected
Lithuanian patients carried at least 1 c.296delGA allele (also referred to
as c.301_302delGA). Until recently gross deletions affecting the
complete PROP1 gene have only been sporadically reported in single
patients from Brazil spanning ~ 18 kb,16 from the United Kingdom
(Kurdish origin, at least 8 kb deleted),19 Turkey (Kurdish origin, at
least 11.7 kb deleted),21 two unrelated Chinese families (at least
53.2 kb deleted)20 and from India (no breakpoint data, see below).18
In 2014 a comprehensive study performed in Turkish CPHD patients
disclosed that a majority of mutational carriers harbored a complete
deletion of PROP1 (8/12 unrelated PROP1 mutation carriers; no
breakpoint data).17
Previous attempts to define the exact deletion breakpoints failed due
to the presence of a duplicated region comprising the non-coding
FAM153C gene upstream of PROP1 (Figure 4). We applied an inverse
PCR approach that requires only one end of the deletion to be defined
roughly to determine both deletion boundaries. All six patients from
three families were found to harbor a 15.9 kb deletion comprising
the PROP1 gene. Sequencing showed that the breakpoints result
from a fusion between two AluY elements down- and upstream of
PROP1, which share 88% identity to each other. Alu elements are
often described as hot spots of mutations.35,36 Non-allelic homologous
recombination of two Alu elements, located on the same chromosome,
leads to deletion or duplication of the sequence between the
Alu elements.35
Our mapping results are in line with the assumption of
Abrão et al.,16 who, for the first time, suggested an Alu sequence-
mediated mechanism for PROP1 excisions. Furthermore, our study














































































































































































































































Figure 5 Pedigree of the family of case 4 and haplotypes of all PROP1 deletion carriers. Index patient of family 4 is indicated by an arrow. Individuals with
PROP1 deletion are depicted with filled symbols, half-filled symbols represent hemizygous carriers. Individuals of generation IV are arranged arbitrarily due to
incomplete birth data. The question mark (IV/4) indicates a sibling for whom DNA was not available. Haplotyping results of STR and SNP (only rs11249784,
rs4507507 and rs1110162 shown) markers are shown below symbols (designation left hand to generation III results). Results are presented as PCR product
length (bp) for STR markers, the specific nucleotide found at the position of SNP markers, and wild-type (WT) or deleted (Δ) genotype for the PROP1 locus.
Shared haplotypes within families are boxed, the conserved region among all deletion carriers is highlighted blue. Closest divergent markers are shown in
bold. Markers that could not be phased are separated by a slash. A full color version of this figure is available at the Journal of Human Genetics journal
online.
Gene deletions causing CPHD
E Bertko et al
760
Journal of Human Genetics
confirms the 3ʹ deletion breakpoint determined by Akcay et al.21 for a
Kurdish CPHD girl. Comparison of size and location of published
deletions with the breakpoint coordinates identified in our study
discloses that deletion carriers of Kurdish descent may harbor the
same or a highly similar mutation, whereas deletions identified in
patients from Brazil, China and India (the latter one assessed in this
study; Figure 4d) differ in size and/or chromosomal position.
However, Alu element-driven recombination may have been the
underlying mechanism in these deletions as well.
To investigate a possible founder effect we performed haplotype
analyses of our three PROP1 index patients and seven relatives of case
4. Only one STR marker (D5S2008) was common to the mutated
allele. Together with the SNP mapping data the putative shared
haplotype comprises a region of at least 350 kb (from rs4507507 to
rs1110162) and at the maximum 423 kb (defined by the closest
divergent markers rs11249784 and D5S2030; Figure 5). Demonstration
of a shared haplotype along with the accumulation of PROP1 deletions
within the regionally/ethnically confined Kurdish population backs the
hypothesis of a founder effect. The finding of a common ancestral
origin of the deletion in our patients is reminiscent of findings for the
c.301_302_delAG PROP1 mutation, which was recently shown to
originate in the majority of European carriers from a common
ancestor, who might have lived ~ 101 generations ago.29
Contrary to PROP1 deletions that occur with high prevalence in the
Kurdish population, only three single cases of POU1F1 deletions have
been reported to date; one of them as compound hemizygous
complete gene deletion in one of the two, first ever reported POU1F1
Dutch families.23 A second case was identified in an Israeli–Arab girl as
a homozygous microdeletion comprising the neighboring CHMP2B
and VGLL3 genes in addition to POU1F1 leading to a contiguous gene
syndrome with clinical features closely related to CPHD and, beyond
that, signs of GH insensitivity.27 A third patient carrying a homo-
zygous deletion of POU1F1 exons 1 and 2 was recently described in
the Turkish CPHD mutational screening.17 Although no refinement of
the deletion boundaries was performed for this patient, it appears
possible that he harbors the same or a similar mutation as our Turkish
patient 1 (c.-1387_214+455del).
Clinical manifestations in our patients confirm the phenotype
classically associated with biallelic PROP1 or POU1F1 mutations, in
line with our finding that neither the PROP1 nor the POU1F1 deletion
affects additional genes. As observed in the majority of previously
reported POU1F1 patients, our patient with POU1F1 gross deletion
presented with GH, TSH and PRL deficits.17,25 MRI, as often described
for POU1F1 defects, displayed a hypoplastic anterior pituitary but
normal pituitary stalk and posterior lobe. Also our patients carrying
PROP1 deletions confirmed findings from previous reports, in that
they had impaired function of somatotropes and gonadotropes as well
as—with some variability despite the same mutation—of thyrotropes
and lactotropes.37–45 Corticotrope insufficiency evolved in one patient
at the age of 13 years that made cortisol substitution necessary and
underlines the need for follow-up monitoring of the adrenal axis in
patients with PROP1 defects.9 MRI of our affected subjects showed
hypoplastic anterior pituitary in two families, whereas the adenohy-
pophysis of the deletion carriers of family 4 was rather normal,
emphasizing morphological variability and lack of correlation between
pituitary size and pituitary function in PROP1 patients.13,17
In conclusion, in this study we show by means of MLPA, deletion
mapping and haplotype analyses that patients with CPHD may carry
large deletions comprising several exons or the entire gene. A PROP1
deletion that starts several kilobases upstream of PROP1 and ends
close to the translation stop probably occurs with relatively high
frequency within populations of Kurdish descent. This deletion
originates most likely from a common ancestor and can be assumed
to be the prevailing CPHD causing aberration in these regions.
In contrast, POU1F1 deletions are rare (likewise point mutations)
without any apparent regional preponderance. Clinical characteristics
of deletion carriers manifest only in the homozygous but not in the
hemizygous state and are indistinguishable from clinical features
typically observed in carriers of POU1F1 or PROP1 point mutations.
MLPA analysis should be considered in the routine diagnostics
of CPHD patients in specific populations or if conventional or
next-generation sequencing techniques yield inconclusive results
(heterozygotes), at least as long as cost-effective, copy number-
sensitive next-generation sequencing methodologies are not available.
Particularly in cases with a dominant familial inheritance pattern
MLPA analysis of samples with negative sequencing results might be
advisable. In Kurdish patients—or if ethnic background is unknown in
patients from Turkey, Syria, Iraq or Iran—long-range PCR as
established in our study may even represent an appropriate comple-
ment to classical Sanger or next-generation sequencing as the first
analytical choice.
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